Bond Teva Pharmaceutical Industries 5.125% ( US88167AAQ40 ) in USD

Teva Pharmaceutical Industries

95.50 % ▼

Israel

US88167AAQ40 ( in USD )

5.125% per year ( payment 2 times a year)

09/05/2029

Prospectus brochure in PDF format

88167AAQ4

BB+ ( Non-investment grade speculative )

Ba1 ( Non-investment grade speculative )

09/11/2026 ( In 67 days )

Teva Pharmaceutical Industries is a global pharmaceutical company specializing in generic and specialty medications, with a focus on central nervous system disorders, respiratory diseases, oncology, and women's health.

This financial article provides an overview of a specific debt instrument issued by Teva Pharmaceutical Industries, a global pharmaceutical leader headquartered in Israel, widely recognized as one of the world's largest manufacturers of generic drugs alongside a significant portfolio of specialty medicines. Identified by ISIN US88167AAQ40 and CUSIP 88167AAQ4, this bond, originating from Israel, is currently quoted on the market at 98.8525% of its face value and is denominated in USD. It carries a fixed annual interest rate of 5.125%, with interest payments disbursed semi-annually (frequency 2), and is set to mature on September 5, 2029. The bond's credit risk profile is evaluated by major rating agencies, holding a BB rating from Standard & Poor's and a Ba1 rating from Moody's.

Date	Clean price
09/03/2026	100.99%
02/01/2026	101.36%
05/11/2025	100.47%
10/09/2025	101.14%
17/07/2025	98.85%
16/05/2025	98.02%
28/02/2025	98.74%
10/01/2025	98.87%
12/11/2024	97.70%
26/09/2024	99.25%
15/09/2024	98.66%
07/08/2024	100.00%
09/08/2023	95.50%
16/07/2023	95.50%
22/06/2023	95.50%
29/05/2023	95.50%
05/05/2023	95.50%
11/04/2023	95.50%
18/03/2023	95.50%
23/02/2023	95.50%
31/01/2023	95.50%
08/01/2023	95.50%
16/12/2022	95.50%
23/11/2022	95.50%
31/10/2022	95.50%
10/10/2022	95.50%
19/09/2022	95.50%
29/08/2022	95.50%
08/08/2022	95.50%
18/07/2022	95.50%
27/06/2022	95.50%
06/06/2022	95.50%
16/05/2022	95.50%
25/04/2022	95.50%
04/04/2022	95.50%